NEW YORK (TheStreet) -- CHANGE IN RATINGS
rated new Buy at Soleil Securities. $65 price target. Risk/reward is favorable, following the recent selloff.
downgraded at Barclays to Underweight from Equal Weight following a negative review of Lorcaserin, its weight loss drug. Price target dropped to $3 from $4. (Note: This drug was earlier cited as Meridia. TheStreet regrets this error.)
downgraded at Wells from Outperform to Market Perform. See little potential upside to HPQ's bid.
Bank of Montreal
downgraded at Credit Suisse to Underperform from Neutral as management hinted towards acquisitions as a means to deploy capital, which raises the bank's risk profile. $61 price target.
Bank of Hawaii
downgraded at Morgan Stanley from Equal-weight to Underweight. Company faces near-term sales headwinds.
( CHSI) rated new Outperform at JMP Securities. Company is a small, but rapidly growing PBM. $53 price target.
initiated at Barclays with an Overweight rating and $22 price target. Attractive valuation and upcoming elections could be a key catalyst, Barclays said.
downgraded at Goldman from Neutral to Sell. $34 price target. Company is struggling to grow sales and could be hurt by higher commodity prices.
downgraded at Jefferies from Hold to Underperform. Valuation call, based on a $31 price target.
downgraded at FBR from Outperform to Market Perform. Valuation call, as end-market growth could begin to slow down.
upgraded at Soleil from Hold to Buy. $20 price target. Tomosynthesis should receive FDA approval.
downgraded at Jefferies from Buy to Hold. $17 price target. Generic Adderall is losing market share.
Lender Processing Services
initiated at Barclays with an Overweight rating and $40 price target. Upcoming election could be a key catalyst and we expect buybacks and acquisitions to drive further earnings growth, Barclays said.
National Bank of Canada
( NA) downgraded at Credit Suisse to Neutral from Outperform. Valuation call. $69 price target.
downgraded at Morgan Stanley from Overweight to Equal-weight. Valuation call, as the stock is up 26% since earnings.
rated new Buy at ThinkEquity. $41 price target. Company is a market leader and should continue to gain market share.
downgraded at Oppenheimer from Outperform to Perform. Recent trip to China, suggests lower demand across the board for the fourth quarter.
rated new Market Perform at JMP. Valuation call, though the company should continue to expand its margins.
rated new Buy at Stifel Nicolaus. $45 price target. Company is growing faster than its end markets in a majority of businesses.
downgraded at Morgan Stanley from Overweight to Equal-weight. Valuation call, a the stock is up 37% over the past year.
rated new Hold at ThinkEquity. $33 price target. Consumer demand shoul remain slow at higher price points, thought the company can continue to gain market share over the next few years.
STOCK COMMENTS / EPS CHANGES
estimates, target reduced at Citigroup. Shares of CAG now seen reaching $30. Estimates also lowered, given lower expected sales. Buy rating.
estimates increased at UBS through 2011. Wind acquisition should add to earnings. Neutral rating and new $26.50 price target.
numbers upped at Citigroup.FII estimates were boosted through 2012. Company is seeing higher bond flows. Hold rating and new $24 price target.
target raised at UBS to $32. Linaclotide trials are progressing well. Neutral rating.
price target higher at Credit Suisse. LRN price target raised by a dollar to $22 on strong 4Q10 results. Maintain Neutral rating.
( PCX) estimates cut at Goldman through 2012. Company is seeing lower production and higher unit cost. Sell rating and $13 price target.
estimates cut at Morgan Stanley through 2012. Box office attendance could tail off by the end of the year. Underweight rating and $13 price target.
estimates, target boosted at UBS. Shares of RVBD now seen reaching $45. Estimates also upped, as the company has several potential growth drivers. Neutral rating.
numbers reduced at Goldman. Shares of SFAM now seen reaching $37. Estimates also cut, because of higher feed prices. Neutral rating.
numbers lowered at Goldman. SFD estimates were reduced through 2012. Company is facing higher feed costs. Buy rating and new $18 price target.
MEMC Electronic Materials
estimates cut at Credit Suisse. WFR 2010, 2011, and 2012 EPS estimates reduced to $0.43, $1.29 and $1.63, respectively. Industry checks in Asia reveal lower panel prices. Maintain Outperform rating and $10.50 price target.
This article was written by a staff member of TheStreet.